Temporal Variation in the Prognosis and Treatment of Advanced Heart Failure - Before and After 2000

Carlo, Carlos Henrique Del; Cardoso, Juliano; Ochia, M. E.; Oliveira, Múcio Tavares de; Ramires, José Antônio Franchini; Pereira-Barretto, Antônio Carlos

doi:10.5935/abc.20140050

Cited by 8 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, Betablocker therapy was an independent predictor of survival. 48 Collectively, the scientific data available at this time suggest that Beta-blocker therapy is not detrimental, and may have a positive impact on patients with Chagas cardiomyopathy with CHF. For this reason, Betablockers have been recommended for the treatment of patients with such a condition.…”

Section: Stage Cmentioning

confidence: 99%

The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era

Bestetti¹,

Daniel²

2016

ICFJ

View full text Add to dashboard Cite

<p>Chronic Heart Failure (CHF) affects about half patients with Chagas cardiomyopathy. Outcome of CHF secondary to Chagas cardiomyopathy is relentless with an annual mortality approaching 20%, which is higher than that observed in non-Chagas disease heart failure. The pathophysiology of Chagas disease is similar to that found in non-Chagas disease heart failure with a marked activation of the neurohormonal system. No randomized trial has been conducted in patients with Chagas cardiomyopathy with CHF to assess the effect of a drug on mortality of such patients. Therefore, the treatment of CHF secondary to Chagas cardiomyopathy relies on drugs prescribed to patients with non-Chagas disease heart failure<strong>. </strong>Patients with Chagas disease heart failure have been classified into stages A to D according to the American College of Cardiology/American Heart Association. Little can be done to patients in the stage A of CHF, except for treatment of comorbidities. In patients in the stage B of CHF, aldosterone receptor antagonist, angiotensin converting enzyme inhibitors (ACEI), and Betablockers (BB) can be indicated. In patients in the stage C of CHF, the same drugs are of value. In addition, diuretics, digoxin, angiotensin receptor blockers to patients intolerant to ACEI have also been used. Cardiac Resynchronization Therapy and Implantable Cardioverter Defibrillator may have indications similar to that of non-Chagas disease patients. In stage D of CHF, heart transplantation is a valid option for patients with this condition. </p>

show abstract

Section: Stage Cmentioning

confidence: 99%

The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era

Bestetti¹,

Daniel²

2016

ICFJ

View full text Add to dashboard Cite

show abstract

“…A probabilidade de sobrevida foi avaliada previamente em casuística no próprio Serviço (Freitas et al, 2005), em 1.220 pacientes com diagnóstico de insuficiência cardíaca sintomática, tratados entre 1991 e 2000, e foi estimada, após um ano de acompanhamento, aproximadamente, em 60%, o que revalida dados publicados de sobrevida estimada entre 40% e 70% (Mady et al, 1994; Pereira Barretto et al, 1998;Carlo et al, 2014;Bocchi et al, 2017 (Freitas et al, 2005). A observação do pior prognóstico dos pacientes com insuficiência cardíaca por doença de Chagas se harmoniza com dados publicados em outras investigações (Espinosa et al, 1985;Mady et al, 1994;Bestetti et al, 1997;Daniel, 2016;Pereira-Barretto et al, 1998;Carlo et al, 2014;Rassi et al, 2010;Bocchi, 2012Bocchi, , 2013Bocchi, , 2017 que, nas formas mais severas da doença, revelaram mortalidade de 80% a 100% em um ano de seguimento (Mady et al, 1994;Theodoropoulos et al, 2008).…”

Section: Conclusõesunclassified

“…Além do tratamento medicamentoso, os processos de transformação inerentes à prática clínica abrangem características dos pacientes, inclusive no acesso às oportunidades de tratamento, progresso na experiência clínica, seja em ferramentas diagnósticas, seja na terapêutica, com a natural consequência na sobrevida em longo prazo (Pitt et al, 1999(Pitt et al, , 2003Bocchi et al, 2008;Issa et al, 2010;Bestetti et al, 2011;Carlo et al, 2014). Portanto, a necessidade de reavaliação periódica do prognóstico dos pacientes é inerente à prática médica.…”

Section: Conclusõesunclassified

“…Trata-se de casuística ambulatorial, diversa de casuísticas de publicações de nosso meio que avaliaram pacientes hospitalizados (Bestetti et al, 1997;Pereira Barretto et al, 1998;Carlo et al, 2014;Albuquerque et al, 2015). (Mady et al, 1994), etiologia da doença de Chagas (Bestetti et al, 1994) ou isquêmica (Lewis et al, 2003), ou fração de ejeção do ventrículo esquerdo inferior ou igual a 40% (Gradman et al,1989).…”

Section: Considerações Sobre As Características Clínicas Dos Pacientesunclassified

“…A frequência de homens em relação a mulheres predominou (64%) na casuística, assim como em outros estudos (Likoff et al, 1987;Bestetti et al, 1997;Lewis et al, 2003;Freitas et al, 2005;Rassi et al, 2006;Ahmed et al, 2006a;Theodoropoulos et al, 2007;Nunes et al, 2008;Marcula et al, 2011;Carlo et al, 2014;Gheorghiade et al, 2013;Abdul-Rahim et al, 2016;Nadruz et al, 2018).…”

Section: Sexounclassified

See 2 more Smart Citations

Avaliação prognóstica em pacientes com insuficiência cardíaca com o emprego de redes neurais artificiais

Marçula¹

View full text Add to dashboard Cite

The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis

Shakoor,

Abou Kamar,

Malgie

et al. 2023

European J of Heart Fail

View full text Add to dashboard Cite

Background and aimsHeart failure (HF) is a chronic and progressive syndrome associated with a poor prognosis. While it may seem intuitive that the risk of adverse outcomes varies across the different stages of HF, an overview of these risks is lacking. This study aims to determine the risk of all‐cause mortality and HF hospitalizations associated with new‐onset HF, chronic HF (CHF), worsening HF (WHF), and advanced HF (adv. HF).MethodsWe performed a systematic review of observational studies from 2012 to 2022 using five different databases. The primary outcomes were 30‐day and one‐year all‐cause mortality, as well as one‐year HF hospitalization. Studies were pooled using random effects meta‐analysis, and mixed‐effects meta‐regression was used to compare the different HF groups.ResultsAmong the 15.759 studies screened, 66 were included representing 862.046 HF patients. Pooled 30‐day mortality rates did not reveal a significant distinction between hospital‐admitted patients, with rates of 10.13% for new‐onset HF and 8.11% for WHF (p = 0.10). However, the one‐year mortality risk differed and increased stepwise from CHF to adv. HF, with a rate of 8.47% (95% CI 7.24–9.89) for CHF, 21.15% (95% CI 17.78–24.95) for new‐onset HF, 26.84% (95% CI 23.74–30.19) for WHF, and 29.74% (95% CI 24.15–36.10) for adv HF. Readmission rates for HF at one year followed a similar trend.ConclusionsOur meta‐analysis of observational studies confirms the different risk for adverse outcomes across the distinct HF stages. Moreover, it emphasizes the negative prognostic value of WHF as the first progressive stage from CHF towards adv. HF.This article is protected by copyright. All rights reserved.

show abstract

Temporal Variation in the Prognosis and Treatment of Advanced Heart Failure - Before and After 2000

Cited by 8 publications

References 23 publications

The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era

The treatment of chronic heart failure secondary to Chagas cardiomyopathy in the contemporary era

Avaliação prognóstica em pacientes com insuficiência cardíaca com o emprego de redes neurais artificiais

The different risk of new‐onset, chronic, worsening, and advanced heart failure: A systematic review and meta‐regression analysis

Contact Info

Product

Resources

About